Xihong Biopharma

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi Xihong Biopharma Co., Ltd, granting CMS exclusive promotion, marketing, and commercialization rights for Xihong Biopharma’s injectable polycaprolactone microspheres filler and injectable hydroxyapatite microspheres filler in China mainland, Hong Kong, Macau, and Taiwan. Both Category III…